询 单
请 填 写 相 关 信 息
产品信息
产品名称
别名
CAS号
结构式 上传
联系方式
公司
联系人
电话
邮箱
内容
提交
中文版 English
请输入产品名称、CAS式、分子式
(1S,2S)-2-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid | CAS:143679-80-5
(1S,2S)-2-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid
  • 名称:(1S,2S)-2-[(叔丁氧羰基)氨基]环戊烷羧酸 | (1S,2S)-2-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid
  • CAS号:143679-80-5
  • 别名:(1S-trans)-2-[[(1,1-Dimethylethoxy)carbonyl]amino]cyclopentanecarboxylic acid
  • 分子式:C11H19NO4
  • 分子量:229.27
  • EINESC号:

产品描述

物理化学性质

密度 1.15

安全数据

没有数据没有数据

SDS

来源 SDS样本
Apollo 浏览或下载
Matrix 浏览或下载
Combi-Blocks 浏览或下载
产品合成路线
更多

名称 CAS号
更多
文章
同行评议文献
Secretion of hydrolytic enzymes by fungal strains, isolated from patients with malignant tumors of head and neck, before, during and after radiotherapy.Salah Moqbil et al.Annals of parasitology, 58(1), 27-35 (2012-10-26) Prevalence of Fabry's disease within hemodialysis patients in Spain.Julio Herrera et al.Clinical nephrology, 81(2), 112-120 (2013-12-25) Fabry disease: dose matters.David G Warnock et al.Journal of the American Society of Nephrology : JASN, 25(4), 653-655 (2014-02-22) [Interrelation of alpha-D-fucosidase and alpha-D-galactosidase activities in man and animals].G Ia Vidershaîn et al.Doklady Akademii nauk SSSR, 231(2), 486-488 (1976-01-01) Angiokeratomas - When is a few too many?Colm O'Mahony et al.International journal of STD & AIDS, 25(5), 378-379 (2013-10-10) Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease.Ester M Pereira et al.Gene, 536(1), 118-122 (2013-12-18) Fabry disease: dose matters.David G Warnock et al.Journal of the American Society of Nephrology : JASN, 25(4), 653-655 (2014-02-22) Cloning, heterologous expression, and characterization of novel protease-resistant α-galactosidase from new Sphingomonas strain.Junpei Zhou et al.Journal of microbiology and biotechnology, 22(11), 1532-1539 (2012-11-06) Streptococcus danieliae sp. nov., a novel bacterium isolated from the caecum of a mouse.Thomas Clavel et al.Archives of microbiology, 195(1), 43-49 (2012-10-12) Prevalence of Fabry's disease within hemodialysis patients in Spain.Julio Herrera et al.Clinical nephrology, 81(2), 112-120 (2013-12-25) Screening human genes for small alterations performing an enzymatic cleavage mismatched analysis (ECMA) protocol.Nikolaos Vogiatzakis et al.Molecular biotechnology, 55(1), 1-9 (2013-08-13) Mir-20a regulates in vitro mineralization and BMP signaling pathway by targeting BMP-2 transcript in fish.Daniel M Tiago et al.Archives of biochemistry and biophysics, 543, 23-30 (2013-12-24) Reference intervals of α-glycosidase, β-glycosidase, and α-galactosidase in dried blood spot in a Turkish newborn population.Ozan Aldemir et al.European journal of pediatrics, 172(9), 1221-1227 (2013-05-11) Fabry disease: is there a role for enzyme replacement therapy?A B Mehta Journal of internal medicine, 274(4), 329-330 (2013-05-15) Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease.Ester M Pereira et al.Gene, 536(1), 118-122 (2013-12-18) Delayed anaphylactic reaction to mammalian meat.K Sekiya et al.Journal of investigational allergology & clinical immunology, 22(6), 446-447 (2012-10-30) Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.Saskia M Rombach et al.PloS one, 7(10), e47805-e47805 (2012-10-25) A thermodynamic assay to test pharmacological chaperones for Fabry disease.Giuseppina Andreotti et al.Biochimica et biophysica acta, 1840(3), 1214-1224 (2013-12-24) Streptococcus dentisani sp. nov., a novel member of the mitis group.Anny Camelo-Castillo et al.International journal of systematic and evolutionary microbiology, 64(Pt 1), 60-65 (2013-09-06) [Home-based infusion therapy--a feasible approach for chronically ill patients? A new path to provide superior patient care exemplified for Fabry's disease].M Beck et al.Deutsche medizinische Wochenschrift (1946), 138(46), 2345-2350 (2013-11-07) Enzyme replacement therapy for Anderson-Fabry disease.Regina P El Dib et al.The Cochrane database of systematic reviews, 2(2), CD006663-CD006663 (2013-03-02) Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers.Janet Hsu et al.Journal of biomedical nanotechnology, 10(2), 345-354 (2014-04-18) Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation.Ilyas Okur et al.Gene, 527(1), 42-47 (2013-06-13) Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.Giovanni Duro et al.Gene, 535(2), 365-369 (2013-10-22) March-in rights under the Bayh-Dole Act: the NIH's paper tiger?William O'Brien Seton Hall law review, 43(4), 1403-1432 (2013-12-07) [Genetic and clinical study of three Chinese pedigrees with Fabry disease].Mao-lu Tian et al.Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 30(2), 185-188 (2013-04-10) Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.Frank Weidemann et al.Journal of the American Society of Nephrology : JASN, 25(4), 837-849 (2014-02-22) Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.Shinkyu Choi et al.Arteriosclerosis, thrombosis, and vascular biology, 34(1), 81-89 (2013-10-26) Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.Antonio Pisani et al.Molecular genetics and metabolism, 107(3), 267-275 (2012-09-12) Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy.Aritz Pérez Ruiz de Garibay et al.Drug design, development and therapy, 6, 303-310 (2012-11-03) Fabry's disease--a comprehensive review on pathogenesis, diagnosis and treatment.Huma Mamun Mahmud JPMA. The Journal of the Pakistan Medical Association, 64(2), 189-194 (2014-03-20) What lies beneath: Fabry nephropathy in a female patient with severe cerebrovascular disease.Elen A Romão et al.Clinical nephrology, 79(4), 330-334 (2013-03-30) Cicer α-galactosidase immobilization onto functionalized graphene nanosheets using response surface method and its applications.Neelesh Singh et al.Food chemistry, 142, 430-438 (2013-09-05) Alpha-galactosidase from Mortierella vinacea. Crystallization and properties.H Suzuki et al.The Journal of biological chemistry, 245(4), 781-786 (1970-02-25) Bifidobacterial α-galactosidase with unique carbohydrate-binding module specifically acts on blood group B antigen.Takura Wakinaka et al.Glycobiology, 23(2), 232-240 (2012-10-24) Diagnosing lysosomal storage disorders: Fabry disease.Olaf A Bodamer et al.Current protocols in human genetics, Chapter 17, Unit17-Unit17 (2013-04-19) The molecular mechanism of thermostable α-galactosidases AgaA and AgaB explained by x-ray crystallography and mutational studies.Romain Merceron et al.The Journal of biological chemistry, 287(47), 39642-39652 (2012-09-27) Raffinose metabolism in Escherichia coli K12. Purification and properties of a new alpha-galactosidase specified by a transmissible plasmid.K Schmid et al.European journal of biochemistry, 67(1), 95-104 (1976-08-01) Red meat allergy in Sweden: association with tick sensitization and B-negative blood groups.Carl Hamsten et al.The Journal of allergy and clinical immunology, 132(6), 1431-1434 (2013-10-08) No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene.Masahisa Kobayashi et al.Molecular genetics and metabolism, 107(4), 711-715 (2012-11-14) Agalsidase benefits renal histology in young patients with Fabry disease.Camilla Tøndel et al.Journal of the American Society of Nephrology : JASN, 24(1), 137-148 (2013-01-01) Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.Dominique P Germain et al.Orphanet journal of rare diseases, 7, 91-91 (2012-11-28) Fabry disease with atypical neurological presentation: report of a case.Costanza Simoncini et al.The neurologist, 18(6), 413-414 (2012-11-02) Application of α-N-acetylgalactosaminidase and α-galactosidase in AB to O red blood cells conversion.Hongwei Gao et al.Artificial cells, nanomedicine, and biotechnology, 41(1), 32-36 (2012-10-04) A revised home treatment algorithm for Fabry disease: influence of antibody formation.B E Smid et al.Molecular genetics and metabolism, 108(2), 132-137 (2013-01-22) Clinical problem-solving. In the thick of it.Deepak A Rao et al.The New England journal of medicine, 368(18), 1732-1738 (2013-05-03) Successful desensitization to agalsidase beta after anaphylaxis.Neetu Talreja et al.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 112(1), 71-72 (2013-12-18) Alpha-galactosidase A activity levels in Turkish male hemodialysis patients.Sema Kalkan Uçar et al.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 16(6), 560-565 (2012-11-30) Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial.Giovanni Di Nardo et al.BMC gastroenterology, 13, 142-142 (2013-09-26) Angiokeratomas - When is a few too many?Colm O'Mahony et al.International journal of STD & AIDS, 25(5), 378-379 (2013-10-10) Cloning, heterologous expression, and characterization of novel protease-resistant α-galactosidase from new Sphingomonas strain.Junpei Zhou et al.Journal of microbiology and biotechnology, 22(11), 1532-1539 (2012-11-06) Improving the binding capacity of Ni2+ decorated porous magnetic silica spheres for histidine-rich protein separation.M Benelmekki et al.Colloids and surfaces. B, Biointerfaces, 101, 370-375 (2012-09-27) Streptococcus danieliae sp. nov., a novel bacterium isolated from the caecum of a mouse.Thomas Clavel et al.Archives of microbiology, 195(1), 43-49 (2012-10-12)
备注

Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).

名称 CAS号

相关产品

相关资讯

热门标签
询 单
请 填 写 相 关 信 息
产品信息
产品名称
别名
CAS号
结构式 上传
联系方式
公司
联系人
电话
邮箱
内容
提交